Search Results - "WELSH, Eric"

Proteomic Analysis of CSF from Patients with Leptomeningeal Melanoma Metastases Identifies Signatures Associated with Disease Progression and Therapeutic Resistance by Smalley, Inna, Law, Vincent, Wyatt, Clayton, Evernden, Brittany, Fang, Bin, Koomen, John M, Welsh, Eric A, Macaulay, Robert J B, Forsyth, Peter A, Smalley, Keiran S M

“…The development of leptomeningeal melanoma metastases (LMM) is a rare and devastating complication of the late-stage disease, for which no effective treatments…”
Get full text

Global Phosphoproteomics Reveal CDK Suppression as a Vulnerability to KRas Addiction in Pancreatic Cancer by Kazi, Aslamuzzaman, Chen, Liwei, Xiang, Shengyan, Vangipurapu, Rajanikanth, Yang, Hua, Beato, Francisca, Fang, Bin, Williams, Terence M, Husain, Kazim, Underwood, Patrick, Fleming, Jason B, Malafa, Mokenge, Welsh, Eric A, Koomen, John, Trevino, José, Sebti, Saïd M

“…Among human cancers that harbor mutant (mt) KRas, some, but not all, are dependent on mt KRas. However, little is known about what drives KRas dependency…”
Get full text

Iterative rank-order normalization of gene expression microarray data by Welsh, Eric A, Eschrich, Steven A, Berglund, Anders E, Fenstermacher, David A

“…Many gene expression normalization algorithms exist for Affymetrix GeneChip microarrays. The most popular of these is RMA, primarily due to the precision and…”
Get full text

Metabolomics of primary cutaneous melanoma and matched adjacent extratumoral microenvironment by Taylor, Nicholas J, Gaynanova, Irina, Eschrich, Steven A, Welsh, Eric A, Garrett, Timothy J, Beecher, Chris, Sharma, Ritin, Koomen, John M, Smalley, Keiran S M, Messina, Jane L, Kanetsky, Peter A

“…Melanoma causes the vast majority of deaths attributable to skin cancer, largely due to its propensity for metastasis. To date, few studies have examined…”
Get full text

A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study by Scott, Jacob G, MD, Berglund, Anders, PhD, Schell, Michael J, Prof, Mihaylov, Ivaylo, PhD, Fulp, William J, MS, Yue, Binglin, MS, Welsh, Eric, PhD, Caudell, Jimmy J, MD, Ahmed, Kamran, MD, Strom, Tobin S, MD, Mellon, Eric, MD, Venkat, Puja, MD, Johnstone, Peter, Prof, Foekens, John, Prof, Lee, Jae, Prof, Moros, Eduardo, Prof, Dalton, William S, Prof, Eschrich, Steven A, PhD, McLeod, Howard, Prof, Harrison, Louis B, Prof, Torres-Roca, Javier F, Dr

“…Summary Background Despite its common use in cancer treatment, radiotherapy has not yet entered the era of precision medicine, and there have been no…”
Get full text

Proteogenomic landscape of squamous cell lung cancer by Stewart, Paul A., Welsh, Eric A., Slebos, Robbert J. C., Fang, Bin, Izumi, Victoria, Chambers, Matthew, Zhang, Guolin, Cen, Ling, Pettersson, Fredrik, Zhang, Yonghong, Chen, Zhihua, Cheng, Chia-Ho, Thapa, Ram, Thompson, Zachary, Fellows, Katherine M., Francis, Jewel M., Saller, James J., Mesa, Tania, Zhang, Chaomei, Yoder, Sean, DeNicola, Gina M., Beg, Amer A., Boyle, Theresa A., Teer, Jamie K., Ann Chen, Yian, Koomen, John M., Eschrich, Steven A., Haura, Eric B.

“…How genomic and transcriptomic alterations affect the functional proteome in lung cancer is not fully understood. Here, we integrate DNA copy number, somatic…”
Get full text

Deciphering Phenotypes from Protein Biomarkers for Translational Research with PIPER by Putty Reddy, Sudhir, Alontaga, Aileen Y., Welsh, Eric A., Haura, Eric B., Boyle, Theresa A., Eschrich, Steven A., Koomen, John M.

“…Liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM) has widespread clinical use for detection of inborn errors of metabolism,…”
Get full text

PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an AKT/mTOR/FRA1 Signaling Axis by Xu, Xiaonan, Bok, Ilah, Jasani, Neel, Wang, Kaizhen, Chadourne, Manon, Mecozzi, Nicol, Deng, Ou, Welsh, Eric A, Kinose, Fumi, Rix, Uwe, Karreth, Florian A

“…Inactivating mutations in PTEN are prevalent in melanoma and are thought to support tumor development by hyperactivating the AKT/mTOR pathway. Conversely,…”
Get full text

IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells by Remsing Rix, Lily L, Sumi, Natalia J, Hu, Qianqian, Desai, Bina, Bryant, Annamarie T, Li, Xueli, Welsh, Eric A, Fang, Bin, Kinose, Fumi, Kuenzi, Brent M, Chen, Y Ann, Antonia, Scott J, Lovly, Christine M, Koomen, John M, Haura, Eric B, Marusyk, Andriy, Rix, Uwe

“…Cancer-associated fibroblasts (CAFs) in the tumor microenvironment are often linked to drug resistance. Here, we found that coculture with CAFs or culture in…”
Get more information

Radiosensitivity of Lung Metastases by Primary Histology and Implications for Stereotactic Body Radiation Therapy Using the Genomically Adjusted Radiation Dose by Ahmed, Kamran A, Scott, Jacob G, Arrington, John A, Naghavi, Arash O, Grass, G Daniel, Perez, Bradford A, Caudell, Jimmy J, Berglund, Anders E, Welsh, Eric A, Eschrich, Steven A, Dilling, Thomas J, Torres-Roca, Javier F

“…We assessed the radiosensitivity of lung metastases on the basis of primary histologic type by using a validated gene signature and model lung metastases for…”
Get more information

Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer by Kim, Jae-Young, Welsh, Eric A, Fang, Bin, Bai, Yun, Kinose, Fumi, Eschrich, Steven A, Koomen, John M, Haura, Eric B

“…Pathway inhibition of the RAS-driven MAPK pathway using small-molecule kinase inhibitors has been a key focus for treating cancers driven by oncogenic RAS, yet…”
Get full text

The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors by Palve, Vinayak, Knezevic, Claire E, Bejan, Daniel S, Luo, Yunting, Li, Xueli, Novakova, Silvia, Welsh, Eric A, Fang, Bin, Kinose, Fumi, Haura, Eric B, Monteiro, Alvaro N, Koomen, John M, Cohen, Michael S, Lawrence, Harshani R, Rix, Uwe

“…PARP inhibitors (PARPis) display single-agent anticancer activity in small cell lung cancer (SCLC) and other neuroendocrine tumors independent of BRCA1/2…”
Get more information

Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma by Fan, Chao, Chen, Lu, Huang, Qingling, Shen, Tao, Welsh, Eric A, Teer, Jamie K, Cai, Jianfeng, Cress, W Douglas, Wu, Jie

“…Background: The cyclin-dependent kinase inhibitor 3 (CDKN3) has been perceived as a tumour suppressor. Paradoxically, CDKN3 is often overexpressed in human…”
Get full text

A Pilot Proteogenomic Study with Data Integration Identifies MCT1 and GLUT1 as Prognostic Markers in Lung Adenocarcinoma by Stewart, Paul A, Parapatics, Katja, Welsh, Eric A, Müller, André C, Cao, Haoyun, Fang, Bin, Koomen, John M, Eschrich, Steven A, Bennett, Keiryn L, Haura, Eric B

“…We performed a pilot proteogenomic study to compare lung adenocarcinoma to lung squamous cell carcinoma using quantitative proteomics (6-plex TMT) combined…”
Get full text

Escape Excel: A tool for preventing gene symbol and accession conversion errors by Welsh, Eric A, Stewart, Paul A, Kuenzi, Brent M, Eschrich, James A

“…Microsoft Excel automatically converts certain gene symbols, database accessions, and other alphanumeric text into dates, scientific notation, and other…”
Get full text

Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells by Kim, Jae-Young, Welsh, Eric A., Oguz, Umut, Fang, Bin, Bai, Yun, Kinose, Fumi, Bronk, Crystina, Rix, Lily L. Remsing, Beg, Amer A., Rix, Uwe, Eschrich, Steven A., Koomen, John M., Haura, Eric B.

“…TANK-binding kinase 1 (TBK1) has emerged as a novel therapeutic target for unspecified subset of lung cancers. TBK1 reportedly mediates prosurvival signaling…”
Get full text

MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling by Chen, Nan, Tyler, Logan C, Le, Anh T, Welsh, Eric A, Fang, Bin, Elliott, Andrew, Davies, Kurtis D, Danhorn, Thomas, Riely, Gregory J, Ladanyi, Marc, Haura, Eric B, Doebele, Robert C

“…Despite the initial benefit from tyrosine kinase inhibitors (TKI) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete…”
Get more information

Genomic identification of sarcoma radiosensitivity and the clinical implications for radiation dose personalization by Yang, George, Yuan, Zhigang, Ahmed, Kamran, Welsh, Eric A., Fulp, William J., Gonzalez, Ricardo J., Mullinax, John E., Letson, Douglas, Bui, Marilyn, Harrison, Louis B., Scott, Jacob G., Torres-Roca, Javier F., Naghavi, Arash O.

“…•Soft tissue sarcomas have traditionally been treated with a one-size fits all approach, despite a wide range of histologies and clinical outcomes.•The…”
Get full text

Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer by Deng, Ou, Dash, Sweta, Nepomuceno, Thales C., Fang, Bin, Yun, Sang Y., Welsh, Eric A., Lawrence, Harshani R., Marchion, Douglas, Koomen, John M., Monteiro, Alvaro N., Rix, Uwe

“…BRCA1/2-deficient ovarian carcinoma (OC) has been shown to be particularly sensitive to poly (ADP-ribose) polymerase inhibitors (PARPis). Furthermore, BRCA1/2…”
Get full text

Tyrosine Kinase Signaling in Clear Cell and Papillary Renal Cell Carcinoma Revealed by Mass Spectrometry-Based Phosphotyrosine Proteomics by Haake, Scott M, Li, Jiannong, Bai, Yun, Kinose, Fumi, Fang, Bin, Welsh, Eric A, Zent, Roy, Dhillon, Jasreman, Pow-Sang, Julio M, Chen, Y Ann, Koomen, John M, Rathmell, W Kimryn, Fishman, Mayer, Haura, Eric B

“…Targeted therapies in renal cell carcinoma (RCC) are limited by acquired resistance. Novel therapeutic targets are needed to combat resistance and, ideally,…”
Get full text